Peptide profile
CJC-1295 (Without DAC)
Natural GH Pulses for Growth and Recovery · also known as Modified GRF 1-29, Mod GRF 1-29, CJC-1295 No DAC, Sermorelin analog
Compare CJC-1295 (Without DAC) with other peptides →Summary
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone in a pulsatile, physiologically natural pattern. It consists of the first 29 amino acids of GHRH with four key amino acid substitutions that enhance stability and receptor affinity compared to the native peptide. It is widely used in research settings for its potential to promote lean muscle growth, fat loss, recovery, and anti-aging effects.
- Typical dose
- 100-300 mcg per injection, 1-3 times daily (often dosed before sleep and/or around training)
- Half-life
- ~30 minutes (biological activity window ~2-3 hours)
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 8-12 weeks, with 4-week breaks recommended
Mechanism
How it works
CJC-1295 without DAC binds to and activates the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, triggering a Gs protein-coupled signaling cascade that elevates intracellular cAMP via adenylyl cyclase activation, ultimately stimulating the synthesis and pulsatile release of growth hormone (GH). Unlike native GHRH (1-44), the four amino acid substitutions (Ala2→D-Ala, Gln8→Ala, Ala15→Ala, Leu27→Val) protect the peptide from enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) and other proteases, extending its half-life to approximately 30 minutes. The resulting GH pulse drives downstream IGF-1 production primarily in the liver, which mediates many of the anabolic, lipolytic, and recovery-related effects.
Reported in research
Benefits
- Promotes pulsatile, physiologically natural growth hormone secretion without desensitizing the pituitary
- Supports increased lean muscle mass through IGF-1-mediated anabolic signaling
- Enhances lipolysis and fat oxidation, particularly visceral and subcutaneous fat reduction
- Accelerates recovery from injury and exercise by promoting tissue repair and collagen synthesis
- May improve sleep quality, particularly slow-wave (deep) sleep duration
- Supports bone mineral density through GH/IGF-1 axis activation
Context, not a prescription
Dosing
- Typical range
- 100-300 mcg per injection, 1-3 times daily (often dosed before sleep and/or around training) (Subcutaneous, Intramuscular)
- Cycle length
- 8-12 weeks, with 4-week breaks recommended
- Half-life
- ~30 minutes (biological activity window ~2-3 hours)
Safety
Side effects & contraindications
Possible side effects
- Transient water retention and mild edema, particularly in the extremities
- Flushing or sensation of warmth shortly after injection
- Injection site redness, mild irritation, or itching
- Tingling or numbness (paresthesia) in the hands or feet
- Headaches, typically mild and transient
- Increased hunger or appetite stimulation
- Potential for hypoglycemia-like symptoms if dosed without food
- Mild fatigue or lethargy in some individuals
Contraindications
- Active malignancy or cancer history — GH elevation may stimulate tumor growth
- Proliferative diabetic retinopathy or severe insulin resistance
- Pregnancy or breastfeeding — safety not established
- Acromegaly or documented GH excess
- Hypersensitivity to GHRH analogs or any peptide components
- Active hypothyroidism — may blunt GH axis response; thyroid status should be optimized first
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Users commonly report better quality of sleep, faster recovery from workouts, reduced soreness, gradual improvements in lean muscle tone, and modest fat loss — particularly around the midsection — over an 8-12 week cycle.
How it works
Think of your pituitary gland as a factory that produces growth hormone. CJC-1295 without DAC is like a short-lived memo that arrives at the factory, triggers a production run, and then disappears quickly — allowing the factory to return to its normal schedule. This is much gentler than continuously running the factory at full capacity.
After you inject it under the skin, it travels through your bloodstream to the pituitary gland, where it docks onto a receptor and triggers a pulse of growth hormone release. This GH then circulates through your body, tells fat cells to release stored fat for energy, and prompts muscle and connective tissue cells to repair and grow. The peptide itself breaks down within about 30 minutes, but the GH pulse it triggered can continue for 2-3 hours.
What to expect
Most users notice improved sleep quality (deeper sleep) within the first 1-2 weeks. Physical changes such as improved recovery and subtle body composition shifts typically begin at 3-6 weeks with consistent use.
- Week 1: The peptide begins stimulating GH pulses. You may notice mild water retention, occasional flushing after injections, and possibly improved sleep depth — especially if dosed before bed.
- Weeks 2-4: Sleep quality typically improves noticeably. Recovery from training sessions begins to feel faster. Energy levels may increase. Water retention from Week 1 usually subsides.
- Weeks 4-8: Body composition changes become noticeable — lean muscle fullness improves and some fat loss, particularly around the midsection, may occur. IGF-1 levels are elevated, supporting tissue repair and overall wellness.
Good to know
- Always inject on an empty stomach or at least 2 hours after a meal to maximize GH release and reduce blood sugar fluctuations
- Start with the lower end of the dose range (100 mcg) to assess your personal tolerance before increasing
- Pair with a GHRP like Ipamorelin rather than GHRP-6 if you want to avoid excessive hunger side effects
- Have bloodwork done before and after a cycle to monitor IGF-1 levels and ensure you stay in a healthy range
Staying safe
- Mild water retention in the first 1-2 weeks that usually resolves on its own
- A warm flushing feeling or mild tingling shortly after injection (lasts 10-30 minutes)
- Slightly increased hunger or appetite
Avoid if you have:
- Anyone with a history of cancer or active tumors
- Pregnant or breastfeeding individuals
- People with uncontrolled diabetes or serious metabolic conditions
- Competitive athletes subject to WADA anti-doping rules
Mechanism of action
CJC-1295 without DAC (Modified GRF 1-29) is a tetrasupstituted GHRH(1-29) analog in which D-Ala replaces Ala at position 2 (DPP-IV cleavage site protection), Gln→Ala at position 8 (chemical stability), Ala→Ala at position 15 (peptidase resistance), and Leu→Val at position 27 (albumin binding reduced, preserving short half-life). It acts as a full agonist at the GHRH receptor (GHRHR), a class B1 GPCR, on anterior pituitary somatotrophs. Receptor binding triggers Gαs-mediated adenylyl cyclase activation, elevating intracellular cAMP, which activates PKA and ultimately phosphorylates CREB to upregulate GH gene transcription and stimulate Ca²⁺-dependent GH vesicle exocytosis. The resulting GH pulse activates JAK2/STAT5 signaling in peripheral tissues, with the liver being the primary source of circulating IGF-1 (principally IGF-1Ea splice variant), which acts via IGF-1R/PI3K/Akt/mTOR pathways to promote anabolism, and via hormone-sensitive lipase activation to enhance lipolysis.
Following subcutaneous administration, absorption is relatively rapid with peak plasma concentrations achieved within 15-20 minutes. The compound's ~30-minute half-life results from a balance between enhanced DPP-IV resistance and the absence of the cysteine-maleimide DAC linker that would otherwise facilitate albumin binding. Peak GH secretion occurs approximately 15-45 minutes post-injection, with GH pulse duration of 90-180 minutes. Endogenous somatostatin tone significantly modulates response amplitude, which is why co-administration with a GHRP (e.g., Ipamorelin or GHRP-2) — which also inhibits somatostatin release — produces synergistic GH elevations of 3-10x compared to either peptide alone. Tachyphylaxis is minimal with pulsatile dosing protocols due to receptor recycling between pulses, unlike continuous GHRH infusion protocols.
Pharmacodynamics
GH pulse is detectable within 15-30 minutes post-injection; plasma GH elevation persists approximately 2-3 hours. IGF-1 elevation requires sustained, repeated dosing — measurable increases in serum IGF-1 typically appear after 7-14 days of consistent administration, with plateau reached around 4-6 weeks. Somatotroph desensitization is minimized by the short half-life when dosed 1-3x per day.
Physiological changes include: (1) anabolic — increased nitrogen retention, mTORC1-mediated protein synthesis, satellite cell activation in skeletal muscle; (2) metabolic — enhanced lipolysis via GH-stimulated hormone-sensitive lipase, reduced lipogenesis, improved insulin sensitivity patterns in the fasting state but potential transient insulin resistance in the fed state; (3) structural — increased collagen synthesis type I and III, improved bone mineral density via osteoblast stimulation; (4) neuroendocrine — improved slow-wave sleep (SWS) architecture as endogenous GH is primarily secreted during SWS; (5) body composition — decreased fat mass (particularly visceral adipose tissue), increased lean body mass.
Timeline
- Days 1-3: CJC-1295 without DAC reaches steady-state receptor occupancy patterns after the first few doses. GH pulses are measurable via serum GH testing 15-45 minutes post-injection. Mild water retention may begin due to sodium retention from GH's effect on renal tubular function. Some users experience transient flushing and injection site responses.
- Weeks 1-2: Serum IGF-1 begins to rise as the cumulative effect of repeated GH pulses activates hepatic JAK2/STAT5-mediated IGF-1 gene transcription. Improved SWS architecture is often reported by the end of week 1-2, consistent with the known role of GH in sleep regulation. Recovery metrics (DOMS reduction, training readiness) begin improving. Transient edema typically peaks and begins resolving.
- Weeks 2-8: IGF-1 reaches a new elevated steady-state (typically 20-40% above baseline with research doses). Anabolic effects on skeletal muscle (mTOR/p70S6K pathway activation, increased protein synthesis rate) become measurable. Lipolytic effects via upregulated hormone-sensitive lipase contribute to progressive fat mass reduction. Collagen synthesis increases, benefiting connective tissue integrity. Long-term receptor sensitivity is maintained due to the pulsatile (non-continuous) dosing pattern.
Comparisons
- CJC-1295 Without DAC (Mod GRF 1-29) — effectiveness High, safety Good, cost $$, Medium to use
- CJC-1295 With DAC — effectiveness High, safety Good, cost $$, Low to use
- Sermorelin — effectiveness Moderate, safety Excellent, cost $, Medium to use
- Tesamorelin — effectiveness Very High, safety Good, cost $$$$, Medium to use
Adverse effects
Common:
- Transient edema from GH-mediated sodium and water retention — due to activation of the renin-angiotensin-aldosterone axis; typically resolves within 2 weeks as IGF-1 normalizes
- Peripheral insulin resistance in the fed state — GH is a counter-regulatory hormone that antagonizes insulin signaling; mitigated by avoiding carbohydrate meals within 2 hours of dosing
- Vasodilation-mediated flushing and warmth — related to GH-induced nitric oxide release; typically lasts 10-30 minutes post-injection
- Paresthesia (tingling/numbness) — likely due to fluid retention affecting peripheral nerve compression (carpal tunnel-like effect); common with higher doses
Rare:
- Antibody formation against the peptide — reported with synthetic GHRH analogs at low incidence (<5% in clinical GHRH analog studies); clinical significance uncertain
- Cortisol and prolactin elevation — GH axis stimulation can transiently elevate stress hormones; rarely clinically significant at research doses
- Exacerbation of pre-existing insulin resistance or progression toward impaired fasting glucose — particularly relevant in individuals with metabolic syndrome
Contraindications & risk mitigation
Contraindicated in:
- Active or prior malignancy — IGF-1 upregulation via GH/IGF-1 axis may accelerate tumor proliferation through IGF-1R signaling; particularly relevant for hormone-sensitive cancers
- Proliferative diabetic retinopathy — GH elevation worsens retinal neovascularization via VEGF upregulation
- Uncontrolled hypothyroidism — thyroid hormone is required for somatotroph responsiveness to GHRH; GH axis stimulation in hypothyroid state may produce blunted or dysregulated responses
- Congestive heart failure with edema — water-retaining effects of GH stimulation may worsen fluid overload
- Acromegaly or documented GH/IGF-1 excess — further axis stimulation is contraindicated
- Monitor serum IGF-1 levels at baseline and at 4-6 weeks to ensure values remain within the physiological reference range for age (typically 100-300 ng/mL); supraphysiological IGF-1 increases risk of adverse effects
- Administer injections in a fasted state (minimum 2 hours post-meal) to avoid GH-insulin antagonism and maximize GH pulse amplitude — postprandial insulin blunts somatotroph GH secretion
- Combine with Ipamorelin rather than GHRP-6 or GHRP-2 for GH synergy if minimizing prolactin, cortisol, and hunger side effects is a priority — Ipamorelin is the most selective GHRP
- Cycle with adequate off-periods (minimum 4 weeks off after 8-12 week cycle) to maintain pituitary sensitivity and prevent receptor downregulation
- Assess thyroid function (TSH, Free T4) prior to use — GH elevation can increase conversion of T4 to reverse T3 (rT3), potentially unmasking subclinical hypothyroidism
Qué hace
Users commonly report better quality of sleep, faster recovery from workouts, reduced soreness, gradual improvements in lean muscle tone, and modest fat loss — particularly around the midsection — over an 8-12 week cycle.
Cómo funciona
Think of your pituitary gland as a factory that produces growth hormone. CJC-1295 without DAC is like a short-lived memo that arrives at the factory, triggers a production run, and then disappears quickly — allowing the factory to return to its normal schedule. This is much gentler than continuously running the factory at full capacity.
After you inject it under the skin, it travels through your bloodstream to the pituitary gland, where it docks onto a receptor and triggers a pulse of growth hormone release. This GH then circulates through your body, tells fat cells to release stored fat for energy, and prompts muscle and connective tissue cells to repair and grow. The peptide itself breaks down within about 30 minutes, but the GH pulse it triggered can continue for 2-3 hours.
Qué esperar
Most users notice improved sleep quality (deeper sleep) within the first 1-2 weeks. Physical changes such as improved recovery and subtle body composition shifts typically begin at 3-6 weeks with consistent use.
- Week 1: The peptide begins stimulating GH pulses. You may notice mild water retention, occasional flushing after injections, and possibly improved sleep depth — especially if dosed before bed.
- Weeks 2-4: Sleep quality typically improves noticeably. Recovery from training sessions begins to feel faster. Energy levels may increase. Water retention from Week 1 usually subsides.
- Weeks 4-8: Body composition changes become noticeable — lean muscle fullness improves and some fat loss, particularly around the midsection, may occur. IGF-1 levels are elevated, supporting tissue repair and overall wellness.
Bueno saber
- Always inject on an empty stomach or at least 2 hours after a meal to maximize GH release and reduce blood sugar fluctuations
- Start with the lower end of the dose range (100 mcg) to assess your personal tolerance before increasing
- Pair with a GHRP like Ipamorelin rather than GHRP-6 if you want to avoid excessive hunger side effects
- Have bloodwork done before and after a cycle to monitor IGF-1 levels and ensure you stay in a healthy range
Manteniéndose seguro
- Mild water retention in the first 1-2 weeks that usually resolves on its own
- A warm flushing feeling or mild tingling shortly after injection (lasts 10-30 minutes)
- Slightly increased hunger or appetite
Evitar si tienes:
- Anyone with a history of cancer or active tumors
- Pregnant or breastfeeding individuals
- People with uncontrolled diabetes or serious metabolic conditions
- Competitive athletes subject to WADA anti-doping rules
Mecanismo de acción
CJC-1295 without DAC (Modified GRF 1-29) is a tetrasupstituted GHRH(1-29) analog in which D-Ala replaces Ala at position 2 (DPP-IV cleavage site protection), Gln→Ala at position 8 (chemical stability), Ala→Ala at position 15 (peptidase resistance), and Leu→Val at position 27 (albumin binding reduced, preserving short half-life). It acts as a full agonist at the GHRH receptor (GHRHR), a class B1 GPCR, on anterior pituitary somatotrophs. Receptor binding triggers Gαs-mediated adenylyl cyclase activation, elevating intracellular cAMP, which activates PKA and ultimately phosphorylates CREB to upregulate GH gene transcription and stimulate Ca²⁺-dependent GH vesicle exocytosis. The resulting GH pulse activates JAK2/STAT5 signaling in peripheral tissues, with the liver being the primary source of circulating IGF-1 (principally IGF-1Ea splice variant), which acts via IGF-1R/PI3K/Akt/mTOR pathways to promote anabolism, and via hormone-sensitive lipase activation to enhance lipolysis.
Following subcutaneous administration, absorption is relatively rapid with peak plasma concentrations achieved within 15-20 minutes. The compound's ~30-minute half-life results from a balance between enhanced DPP-IV resistance and the absence of the cysteine-maleimide DAC linker that would otherwise facilitate albumin binding. Peak GH secretion occurs approximately 15-45 minutes post-injection, with GH pulse duration of 90-180 minutes. Endogenous somatostatin tone significantly modulates response amplitude, which is why co-administration with a GHRP (e.g., Ipamorelin or GHRP-2) — which also inhibits somatostatin release — produces synergistic GH elevations of 3-10x compared to either peptide alone. Tachyphylaxis is minimal with pulsatile dosing protocols due to receptor recycling between pulses, unlike continuous GHRH infusion protocols.
Farmacodinamia
GH pulse is detectable within 15-30 minutes post-injection; plasma GH elevation persists approximately 2-3 hours. IGF-1 elevation requires sustained, repeated dosing — measurable increases in serum IGF-1 typically appear after 7-14 days of consistent administration, with plateau reached around 4-6 weeks. Somatotroph desensitization is minimized by the short half-life when dosed 1-3x per day.
Physiological changes include: (1) anabolic — increased nitrogen retention, mTORC1-mediated protein synthesis, satellite cell activation in skeletal muscle; (2) metabolic — enhanced lipolysis via GH-stimulated hormone-sensitive lipase, reduced lipogenesis, improved insulin sensitivity patterns in the fasting state but potential transient insulin resistance in the fed state; (3) structural — increased collagen synthesis type I and III, improved bone mineral density via osteoblast stimulation; (4) neuroendocrine — improved slow-wave sleep (SWS) architecture as endogenous GH is primarily secreted during SWS; (5) body composition — decreased fat mass (particularly visceral adipose tissue), increased lean body mass.
Cronología
- Days 1-3: CJC-1295 without DAC reaches steady-state receptor occupancy patterns after the first few doses. GH pulses are measurable via serum GH testing 15-45 minutes post-injection. Mild water retention may begin due to sodium retention from GH's effect on renal tubular function. Some users experience transient flushing and injection site responses.
- Weeks 1-2: Serum IGF-1 begins to rise as the cumulative effect of repeated GH pulses activates hepatic JAK2/STAT5-mediated IGF-1 gene transcription. Improved SWS architecture is often reported by the end of week 1-2, consistent with the known role of GH in sleep regulation. Recovery metrics (DOMS reduction, training readiness) begin improving. Transient edema typically peaks and begins resolving.
- Weeks 2-8: IGF-1 reaches a new elevated steady-state (typically 20-40% above baseline with research doses). Anabolic effects on skeletal muscle (mTOR/p70S6K pathway activation, increased protein synthesis rate) become measurable. Lipolytic effects via upregulated hormone-sensitive lipase contribute to progressive fat mass reduction. Collagen synthesis increases, benefiting connective tissue integrity. Long-term receptor sensitivity is maintained due to the pulsatile (non-continuous) dosing pattern.
Comparaciones
- CJC-1295 Without DAC (Mod GRF 1-29) — efectividad High, seguridad Good, costo $$, Medium de usar
- CJC-1295 With DAC — efectividad High, seguridad Good, costo $$, Low de usar
- Sermorelin — efectividad Moderate, seguridad Excellent, costo $, Medium de usar
- Tesamorelin — efectividad Very High, seguridad Good, costo $$$$, Medium de usar
Efectos adversos
Comunes:
- Transient edema from GH-mediated sodium and water retention — due to activation of the renin-angiotensin-aldosterone axis; typically resolves within 2 weeks as IGF-1 normalizes
- Peripheral insulin resistance in the fed state — GH is a counter-regulatory hormone that antagonizes insulin signaling; mitigated by avoiding carbohydrate meals within 2 hours of dosing
- Vasodilation-mediated flushing and warmth — related to GH-induced nitric oxide release; typically lasts 10-30 minutes post-injection
- Paresthesia (tingling/numbness) — likely due to fluid retention affecting peripheral nerve compression (carpal tunnel-like effect); common with higher doses
Raros:
- Antibody formation against the peptide — reported with synthetic GHRH analogs at low incidence (<5% in clinical GHRH analog studies); clinical significance uncertain
- Cortisol and prolactin elevation — GH axis stimulation can transiently elevate stress hormones; rarely clinically significant at research doses
- Exacerbation of pre-existing insulin resistance or progression toward impaired fasting glucose — particularly relevant in individuals with metabolic syndrome
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Active or prior malignancy — IGF-1 upregulation via GH/IGF-1 axis may accelerate tumor proliferation through IGF-1R signaling; particularly relevant for hormone-sensitive cancers
- Proliferative diabetic retinopathy — GH elevation worsens retinal neovascularization via VEGF upregulation
- Uncontrolled hypothyroidism — thyroid hormone is required for somatotroph responsiveness to GHRH; GH axis stimulation in hypothyroid state may produce blunted or dysregulated responses
- Congestive heart failure with edema — water-retaining effects of GH stimulation may worsen fluid overload
- Acromegaly or documented GH/IGF-1 excess — further axis stimulation is contraindicated
- Monitor serum IGF-1 levels at baseline and at 4-6 weeks to ensure values remain within the physiological reference range for age (typically 100-300 ng/mL); supraphysiological IGF-1 increases risk of adverse effects
- Administer injections in a fasted state (minimum 2 hours post-meal) to avoid GH-insulin antagonism and maximize GH pulse amplitude — postprandial insulin blunts somatotroph GH secretion
- Combine with Ipamorelin rather than GHRP-6 or GHRP-2 for GH synergy if minimizing prolactin, cortisol, and hunger side effects is a priority — Ipamorelin is the most selective GHRP
- Cycle with adequate off-periods (minimum 4 weeks off after 8-12 week cycle) to maintain pituitary sensitivity and prevent receptor downregulation
- Assess thyroid function (TSH, Free T4) prior to use — GH elevation can increase conversion of T4 to reverse T3 (rT3), potentially unmasking subclinical hypothyroidism
Reference data
Specifications
- Molecular formula
- C152H252N44O42
- Molecular weight
- 3367.97 g/mol
- Half-life
- ~30 minutes (biological activity window ~2-3 hours)
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 8-12 weeks, with 4-week breaks recommended
- Storage
- Lyophilized (dry) powder: store at 2–8°C (refrigerator) away from light; stable up to 24 months. After reconstitution with bacteriostatic water: store at 2–8°C and use within 28–30 days. Never freeze reconstituted solution. Keep away from direct sunlight and heat.
- Legal status
- Research chemical only in most jurisdictions; not FDA-approved for human therapeutic use. Prohibited in competitive sports by WADA. Legal to purchase for research in the US, Canada, and Australia with restrictions.
FAQ
Common questions
What is the pharmacokinetic rationale for preferring Mod GRF 1-29 over native GHRH or Sermorelin?
Native GHRH(1-44) has a plasma half-life of approximately 7 minutes due to rapid N-terminal cleavage by DPP-IV. Sermorelin (GHRH 1-29) improves on this marginally (~10-12 min). Modified GRF 1-29 extends bioavailability to ~30 minutes via D-Ala substitution at position 2 (DPP-IV cleavage site) and three additional stabilizing substitutions, while intentionally avoiding the albumin-binding DAC modification to preserve pulsatile pharmacokinetics. The result is a more receptor-selective, proteolysis-resistant molecule that produces physiologically patterned GH release.
How does the synergy with GHRPs work mechanistically?
GHRH (and CJC-1295 w/o DAC) acts through GHRHR/Gαs/cAMP to stimulate GH synthesis and release. GHRPs (e.g., Ipamorelin, GHRP-2) act through the ghrelin receptor (GHS-R1a), a Gαq/11-coupled GPCR, which independently stimulates IP3/DAG/PKC signaling and intracellular Ca²⁺ mobilization. GHRPs also inhibit somatostatin (SST) release from the hypothalamus, removing the primary inhibitory brake on GH secretion. The dual-pathway activation produces GH pulse amplitudes 3-10x greater than either agent alone, consistent with the concept of 'primed' somatotroph response.
Is there a risk of pituitary downregulation with long-term use?
Continuous GHRH infusion studies have demonstrated somatotroph desensitization via GHRHR downregulation and uncoupling from Gαs. However, pulsatile administration mimicking endogenous GHRH rhythms (which occur every 3-4 hours) allows receptor recycling and resensitization between doses. Clinical studies with GHRH analogs (particularly Tesamorelin — a related GHRH analog FDA-approved for HIV-associated lipodystrophy) administered daily for up to 52 weeks showed sustained efficacy without significant tachyphylaxis, supporting the safety of intermittent dosing protocols.
What is the evidence level?
This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.
Research
Research & sources
Current evidence for CJC-1295 (Without DAC) is rated as Limited human data. Limited human data is available.
- 1. Stimulation of growth hormone (GH) secretion by a novel synthetic GH-releasing peptide: comparison with GH-releasing hormone (GHRH) and Hexarelin (1997) — Journal of Endocrinology
- 2. Effects of once weekly dosing of a growth hormone-releasing hormone analog (CJC-1295) on growth hormone and insulin-like growth factor-1 levels in healthy adults (2006) — Journal of Clinical Endocrinology & Metabolism, 91(3):799-805
- 3. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (2011) — Expert Opinion on Pharmacotherapy, 12(14):2237-2251
- 4. Growth hormone-releasing hormone: clinical studies and therapeutic aspects (1998) — Endocrine Reviews, Endocrine Society
- 5. Ghrelin and the GH secretagogue receptor: from discovery to biomarker (2014) — Frontiers in Endocrinology
Explore